There is insufficient indicant to confirm or refute.

Spot trials including 6997 participants (995 with detectable microfilariae) met the criteria. A alikeness of albendazole and medication detected no validity on microfilariae preponderance (920 participants; 3 trials); one legal proceeding (499 participants) reported significantly lower microfilariae denseness at six months. Albendazole performed slightly worse than ivermectin in two trials (436 participants). Compared with diethylcarbamazine (DEC), two size trials (56 participants) found little number in microfilariae ratio over an extended follow up. One larger competition (502 participants) found a statistically significant gist for DEC at six months, but none at ternary months.
Microfilariae generality and spacing were statistically significantly lower with the coalition of albendazole and ivermectin compared with ivermectin alone in two of threesome trials (649 participants). Two trials compared albendazole plus DEC with DEC alone and found no statistically significant fluctuation in microfilariae number, though one attempt favoured the aggregation at six months (relative risk 0.62, 95% sureness distance 0.32 to 1.21; 491 participants). This contest also found a statistically significant reaction in microfilariae spatial arrangement.
There is insufficient indicant to confirm or refute that albendazole co – administered with DEC or ivermectin is more effective than DEC or ivermectin alone in tract microfilariae or cleanup creature worms. Albendazole combined with ivermectin appears to have a size result on microfilaraemia, but this was not consistently demonstrated.